What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Promising retinitis pigmentosa results have given Reneuron a boost, but the company still faces a pivotal trial.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?